134 related articles for article (PubMed ID: 17178869)
21. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice.
del Rey MJ; Izquierdo E; Caja S; Usategui A; Santiago B; Galindo M; Pablos JL
Arthritis Rheum; 2009 Oct; 60(10):2926-34. PubMed ID: 19790065
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels.
Lövey J; Bereczky B; Gilly R; Kenessey I; Rásó E; Simon E; Dobos J; Vágó A; Kásler M; Döme B; Tímár J; Tóvári J
Strahlenther Onkol; 2008 Jan; 184(1):1-7. PubMed ID: 18188516
[TBL] [Abstract][Full Text] [Related]
23. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.
Kudo T; Ueda M; Kuge Y; Mukai T; Tanaka S; Masutani M; Kiyono Y; Kizaka-Kondoh S; Hiraoka M; Saji H
J Nucl Med; 2009 Jun; 50(6):942-9. PubMed ID: 19443598
[TBL] [Abstract][Full Text] [Related]
24. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
Merighi S; Benini A; Mirandola P; Gessi S; Varani K; Simioni C; Leung E; Maclennan S; Baraldi PG; Borea PA
Mol Pharmacol; 2007 Aug; 72(2):395-406. PubMed ID: 17488804
[TBL] [Abstract][Full Text] [Related]
25. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells.
Alqawi O; Wang HP; Espiritu M; Singh G
Free Radic Res; 2007 Jul; 41(7):788-97. PubMed ID: 17577739
[TBL] [Abstract][Full Text] [Related]
26. The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction.
Tanaka T; Wiesener M; Bernhardt W; Eckardt KU; Warnecke C
Biochem J; 2009 Oct; 424(1):143-51. PubMed ID: 19694616
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Simiantonaki N; Jayasinghe C; Michel-Schmidt R; Peters K; Hermanns MI; Kirkpatrick CJ
Int J Oncol; 2008 Mar; 32(3):585-92. PubMed ID: 18292935
[TBL] [Abstract][Full Text] [Related]
28. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
Shi M; Guo XT; Shu MG; Chen FL; Li LW
Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-driven proliferation of embryonic neural stem/progenitor cells--role of hypoxia-inducible transcription factor-1alpha.
Zhao T; Zhang CP; Liu ZH; Wu LY; Huang X; Wu HT; Xiong L; Wang X; Wang XM; Zhu LL; Fan M
FEBS J; 2008 Apr; 275(8):1824-34. PubMed ID: 18341590
[TBL] [Abstract][Full Text] [Related]
30. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
Potiron VA; Sharma G; Nasarre P; Clarhaut JA; Augustin HG; Gemmill RM; Roche J; Drabkin HA
Cancer Res; 2007 Sep; 67(18):8708-15. PubMed ID: 17875711
[TBL] [Abstract][Full Text] [Related]
31. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model.
Kamlah F; Eul BG; Li S; Lang N; Marsh LM; Seeger W; Grimminger F; Rose F; Hänze J
Cancer Gene Ther; 2009 Mar; 16(3):195-205. PubMed ID: 18818708
[TBL] [Abstract][Full Text] [Related]
32. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors.
Cairns RA; Kalliomaki T; Hill RP
Cancer Res; 2001 Dec; 61(24):8903-8. PubMed ID: 11751415
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of ischemic preconditioning and postconditioning as putative therapeutic targets to reduce tumor survival and malignancy.
Muscari C; Giordano E; Bonafè F; Govoni M; Pasini A; Guarnieri C
Med Hypotheses; 2013 Dec; 81(6):1141-5. PubMed ID: 24230458
[TBL] [Abstract][Full Text] [Related]
34. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma.
Kimura H; Braun RD; Ong ET; Hsu R; Secomb TW; Papahadjopoulos D; Hong K; Dewhirst MW
Cancer Res; 1996 Dec; 56(23):5522-8. PubMed ID: 8968110
[TBL] [Abstract][Full Text] [Related]
35. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response.
Vaupel P; Harrison L
Oncologist; 2004; 9 Suppl 5():4-9. PubMed ID: 15591417
[TBL] [Abstract][Full Text] [Related]
36. Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?
Denekamp J; Daşu A; Waites A
Adv Enzyme Regul; 1998; 38():281-99. PubMed ID: 9762359
[TBL] [Abstract][Full Text] [Related]
37. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy.
Green SL; Giaccia AJ
Cancer J Sci Am; 1998; 4(4):218-23. PubMed ID: 9689978
[No Abstract] [Full Text] [Related]
38. Quantitative spatial analysis of hypoxia and vascular perfusion in tumor sections.
Busch TM; Wileyto EP; Evans SM; Koch CJ
Adv Exp Med Biol; 2003; 510():37-43. PubMed ID: 12580402
[No Abstract] [Full Text] [Related]
39. Cyclic Hypoxia: An Update on Its Characteristics, Methods to Measure It and Biological Implications in Cancer.
Bader SB; Dewhirst MW; Hammond EM
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374581
[TBL] [Abstract][Full Text] [Related]
40. A reason for intermittent fasting to suppress the awakening of dormant breast tumors.
Lankelma J; Kooi B; Krab K; Dorsman JC; Joenje H; Westerhoff HV
Biosystems; 2015 Jan; 127():1-6. PubMed ID: 25448890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
